Amgen announced on Tuesday the submission of a supplemental Biologics License Application to the FDA for Blincyto, or blinatumomab, to include overall survival data from the phase 3 TOWER study, supporting the conversion of Blincyto’s accelerated approval to full approval.
For a year before an osteosarcoma was found in her right proximal tibia, Sammy Ulloa, pushing through pain, persisted with her training as a Division I track and field and cross-country competitor.
